Standard Biotools (LAB) Long-Term Investments (2011 - 2026)

Standard Biotools' (LAB) quarterly Long-Term Investments came in at $71.4 million in Q1 2026, up 177.64% on a QoQ basis from $25.7 million in Q4 2025.

Standard Biotools (LAB) Long-Term Investments (2011 - 2026) Analysis & Trends

Standard Biotools (LAB) has 7 years of Long-Term Investments data on file, last reported at $71.4 million in Q1 2026.

  • On a quarterly basis, Long-Term Investments changed N/A year-over-year to $71.4 million in Q1 2026; TTM through Mar 2026 was $71.4 million, a N/A change from a year earlier, with the FY2025 full-year figure at $25.7 million, changed N/A from the prior year.
  • Long-Term Investments for Q1 2026 stood at $71.4 million, up from $25.7 million in the prior quarter.
  • Over the last five years, Long-Term Investments for LAB reached as high as $71.4 million in Q1 2026 and fell as low as $19.5 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Investments (Qtr)
1 Abbott Laboratories 182.32 Bn 175.02 Bn 6.27 Bn 1.09 Bn
2 Stryker 128.75 Bn 125.88 Bn 3.81 Bn -
3 Medtronic 107.83 Bn 98.61 Bn 6.41 Bn -
4 Boston Scientific 67.61 Bn 66.15 Bn 3.61 Bn -
5 Edwards Lifesciences 48.13 Bn 44.45 Bn 1.29 Bn 285.60 Mn
6 Dexcom 28.26 Bn 27.14 Bn 750.30 Mn -
7 GE HealthCare Technologies 27.78 Bn 25.50 Bn 1.98 Bn -
8 Smith & Nephew 26.99 Bn 26.41 Bn - 121.00 Mn
9 Koninklijke Philips 23.92 Bn 20.80 Bn 2.07 Bn 166.25 Mn
10 Standard Biotools 299.46 Mn -155.72 Mn 11.31 Mn 71.36 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 71.36 Mn
Dec 31, 2025 25.70 Mn
Sep 30, 2025 19.49 Mn
Dec 31, 2015 6.49 Mn
Sep 30, 2015 17.03 Mn
Jun 30, 2015 27.12 Mn
Mar 31, 2015 18.51 Mn
Dec 31, 2014 27.50 Mn
Sep 30, 2014 51.96 Mn
Jun 30, 2014 62.29 Mn
Mar 31, 2014 15.13 Mn
Dec 31, 2013 1.94 Mn
Sep 30, 2013 19.14 Mn
Jun 30, 2013 23.07 Mn
Mar 31, 2013 7.30 Mn
Dec 31, 2012 3.67 Mn
Sep 30, 2012 3.20 Mn
Jun 30, 2012 1.00 Mn
Mar 31, 2012 6.07 Mn
Dec 31, 2011 1.50 Mn